
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
Pharmaceutical Executive’s Lisa Henderson interviews Todd Phillips, PharmD, of Cardinal Health Regulatory Sciences about FDA’s expedited programs and key elements to consider before using this pathway.






